Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin Lymphoma from the Lymphoma and Related Diseases Registry.
James NguyenCameron WellardEliza ChungChan Y CheahMichael DickinsonNicole Wong DooColm KeaneDipti TalaulikarLeanne BerkahnSusan MorganNada HamadTara CochraneAnna M JohnstonCecily ForsythStephen OpatAllison BarracloughHoward MutsandoSumita RatnasingamPratyush GiriErica M WoodZoe K McQuiltenEliza A Hawkesnull nullPublished in: European journal of haematology (2022)
Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real-world data of 498 eligible patients from the first five years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype and treatment patterns in first-line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) was the most common therapy for both early and advanced-stage disease, and 48% of patients with early-stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥ 60 years of age with advanced-stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early-stage disease, and 88% in advanced-stage disease. Early progression-free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.
Keyphrases
- hodgkin lymphoma
- early stage
- end stage renal disease
- chronic kidney disease
- ejection fraction
- type diabetes
- free survival
- peritoneal dialysis
- machine learning
- patient reported outcomes
- bone marrow
- drug delivery
- case report
- metabolic syndrome
- mesenchymal stem cells
- combination therapy
- clinical practice
- locally advanced
- drug induced
- pulmonary fibrosis
- data analysis
- cell therapy
- neoadjuvant chemotherapy